Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
Total Valuation
Marker Therapeutics has a market cap or net worth of $12.53M. The enterprise value is $9.11M.
Market Cap$12.53M
Enterprise Value$9.11M
Share Statistics
Marker Therapeutics has 10.71M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10.71M
Owned by Insiders43.35%
Owned by Instutions32.34%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is -103.79%.
Return on Equity (ROE)-99.95%
Return on Assets (ROA)-82.01%
Return on Invested Capital (ROIC)-103.79%
Return on Capital Employed (ROCE)-103.76%
Revenue Per Employee$674,481.125
Profits Per Employee-$1,204,227.25
Employee Count8
Asset Turnover0.19
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is -3.45. Marker Therapeutics’s PEG ratio is 0.07.
PE Ratio-3.45
PS Ratio14.63
PB Ratio3.45
Price to Fair Value3.45
Price to FCF-2.95
Price to Operating Cash Flow-2.95
PEG Ratio0.07
Income Statement
In the last 12 months, Marker Therapeutics had revenue of $5.40M and earned -$9.63M in profits. Earnings per share was -$1.09.
Revenue$5.40M
Gross Profit$203.52K
Operating Income-$10.19M
Pretax Income-$9.63M
Net Income-$9.63M
EBITDA-10.19M
Earnings Per Share (EPS)-1.09
Cash Flow
In the last 12 months, operating cash flow was -$8.57M and capital expenditures $0.00, giving a free cash flow of -$8.57M billion.
Operating Cash Flow-$8.57M
Free Cash Flow-$8.57M
Free Cash Flow per Share-$0.80
Dividends & Yields
Marker Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-33.93%
Earnings Yield-28.99%
Stock Price Statistics
Beta1.75
52-Week Price Change-74.94%
50-Day Moving Average1.39
200-Day Moving Average3.01
Relative Strength Index (RSI)41.91
Average Volume (3m)189.66K
Important Dates
Marker Therapeutics upcoming earnings date is May 20, 2025, TBA.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Marker Therapeutics as a current ratio of 5.57, with Debt / Equity ratio of 0.00
Current Ratio5.57
Quick Ratio5.57
Debt to Market Cap0.00
Net Debt to EBITDA1.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marker Therapeutics has paid -$2.55M in taxes.
Income Tax-$2.55M
Effective Tax Rate-0.03%
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is -2.83, with an EV/FCF ratio of -2.03.
EV to Sales10.07
EV to EBITDA-2.83
EV to Free Cash Flow-2.03
EV to Operating Cash Flow-2.03
Balance Sheet
Marker Therapeutics has $9.00M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$9.00M billion.
Cash & Marketable Securities$9.00M
Total Debt$0.00
Net Cash-$9.00M
Net Cash Per Share-$0.84
Tangible Book Value Per Share$1.60
Margins
Gross margin is -214.60%, with operating margin of -440.37%, and net profit margin of -424.20%.
Gross Margin-214.60%
Operating Margin-440.37%
Pretax Margin-424.09%
Net Profit Margin-424.20%
EBITDA Margin-356.14%
EBIT Margin-424.09%
Analyst Forecast
The average price target for Marker Therapeutics is $8.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.17
Price Target Upside656.48%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-3.23%
EPS Growth Forecast38.05%